Adipose (fat) tissue is readily available and has been shown to be rich in microvascular, myogenic and angiogenic cells. In collaboration with the Regenerative Medicine Institute in Tijuana, Mexico, congestive heart failure patients are being treated in a Phase I/II trial at Hospital Angeles Tijuana. These patients have demonstrated on average an absolute improvement of 13 percentage points in ejection fraction and an increase of 100 meters in their six minute walk distance.
Bioheart has recently applied to the FDA to begin trials using adipose derived stem cells or LipiCell™ in patients with chronic ischemic cardiomyopathy. The therapy involves the use of stem cells derived from the patient’s own fat (adipose tissue) obtained using liposuction. Transplantation of LipiCell™ is accomplished through endocardial implantations with an injection catheter.